By Fineline Cube 
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced that it has received approval from China’s National Medical Products Administration (NMPA) for its BroncAblate disposable pulmonary radiofrequency ablation catheter. This marks a significant advancement in the treatment of lung tumors with a minimally invasive approach.
BroncAblate: Innovation in Lung Cancer Therapy
BroncAblate is recognized as the world’s first natural cavity radiofrequency ablation device designed specifically for lung cancer treatment. The device delivers radiofrequency intervention therapy to the center of lung lesions via the natural lumen (bronchus). By inactivating tumor tissue through radiofrequency ablation, BroncAblate offers a precise, targeted, and ultrafine interventional therapy that is both minimally invasive and reproducible.
Clinical Validation and Benefits
The regulatory BRONC-RFII study has confirmed the safety and efficacy of BroncAblate in treating lung tumors. This innovative approach provides a new therapeutic option for patients, combining accuracy and effectiveness in a minimally invasive procedure.-Fineline Info & Tech